Claim: The dose schedule for Tirzepatide, which starts at 2.5 milligrams and goes up to 15 milligrams, is based on how the drug was studied in trials and not tailored to individual patient needs.
Verdict: Partially True (60% confidence)
Explanation: The claim states that the dose schedule for Tirzepatide starts at 2.5 mg and goes up to 15 mg, which is supported by the PMC article by JP Frias. The StatPearls entry by K Farzam confirms that this schedule is based on clinical trials. However, the evidence does not explicitly state that the dosing schedule is not tailored to individual patient needs, leaving this part of the claim unverified. Therefore, while the dosing schedule and its basis in trials are supported, the claim about lack of ind...